Business Context and Reporting Period
This Form 8-K is a current report filed by Atyr Pharma, Inc. on August 15, 2018. The filing addresses a change in the Company's senior financial leadership effective August 15, 2018.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Appointment: Jill M. Broadfoot, the Company's Chief Financial Officer, was appointed as the principal financial officer and principal accounting officer.
- Resignation: Stan Blackburn resigned from the positions of principal financial officer and principal accounting officer.
- Effective Date: Both the appointment and resignation are effective as of August 15, 2018.
- Post-Resignation Role: Mr. Blackburn continues to serve as a financial consultant to the Company following his resignation.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on financial performance, risks, contingencies, or unusual items. The document is limited to the disclosure of the officer departure and appointment.
Investor Verification Checklist
- Verify the transition timeline between Stan Blackburn and Jill M. Broadfoot to ensure continuity in financial reporting.
- Review the terms of Mr. Blackburn's ongoing role as a financial consultant for potential conflicts of interest or additional compensation.
- Confirm the Company's compliance with SEC requirements regarding the appointment of a new principal accounting officer.